Exeltis Turkey, who
starts off from the slogan “We see knowledge as a key factor to execute our
commitment to human health and welfare” and who lives on a quality and innovation
oriented, strong R&D culture, has been developing licensed and eligible
goods in the areas of vaginitis, dermatology, topical ache, oral contraceptive,
and respiration.
In the duration from
Phase 1 studies to the approval, the Research and Development activities of
Exeltis Turkey are undertaken in a specialized way with the potential of CHEMO
Group and the potential provided by our worldwide associations and the
corporate research centre Ladee Pharma Research Institute (LPRI).
Working synergistically
with the R&D department, the Business Development department of Exeltis
Turkey has been shaping the firm’s future according to the needs of patient and
doctor with the aim of improving the product portfolio.
Exeltis Turkey is
composed of patent lawyers experienced in R&D, pharmacists that have
academic competence, pharmaceutical technologists, chemical engineers,
microbiologists, and pharmacologists.
Research and evaluation
of patent, formulation, and analytical method and product development, clinical
studies, test and pilot production performed in laboratories, process and
analytical method validations, product recovery works, stability of new
products and technology transfer works, preparation works of license files in
CDT format are fulfilled with Quality by Design (QbD) mentality and
state-of-the-art technology production equipment and within the frame of
international codes of conduct and in compliance with the conditions of
international Good Laboratory Practice (GLP) and Good Manufacturing Practice
(GMP), which are determined by World Health Organization.
Exeltis also collaborates with international research and development companies at different phases of projects for developing new product. The value that Exeltis Turkey has got derives from its ability of new Intellectual Property, which is continuously maintained over drug release technologies at niche treatment areas, where it retains its leadership. Patent applications for all the products developed are made in the USA and at international platforms. Alongside possessing a lot of patents certified by both the USA and other countries, Exeltis Turkey has plenty of patents whose applications have been made or preparing to be made as part of Patent Cooperation Treaty (PTC). Some primary technologies developed by Exeltis Turkey that are patented are LPSTM, Lamellar Penetration system and microsponge system. Moreover, there are many TÜBİTAK-TEYDEB supported projects that are currently being conducted at our R&D centre.
